In vitro postantibiotic effects of tomopenem (CS-023)against Staphylococcus aureus and Pseudomonas aeruginosa

Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Tomopenem (formerly CS-023) is a novel 1beta-methylcarbapenem with broad-spectrum coverage of gram-positive and gram-negative pathogens. Its antibacterial activity against European clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa was compared with those of imipenem and meropenem. The MICs of tomopenem against MRSA and P. aeruginosa at which 90% ...

In vitro Evaluation of Methylxanthines and Some Antibiotics: Interaction against Staphylococcus aureus and Pseudomonas aeruginosa

Background: The development of resistance to antimicrobial agents is a major problem in chemotherapy. Finding agents which potentiate antimicrobial activity could be favorable. There are some reports that methylxanthines changed the inhibitory effect of antibacterial agents. Thus, possible synergistic effect of methylxanthines, aminophylline and caffeine on some antibiotics, carbenicillin, ceft...

Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.

Tomopenem (formerly CS-023), a novel 1beta-methylcarbapenem, exhibited high affinity for penicillin-binding protein (PBP) 2 in Staphylococcus aureus, PBP 2 in Escherichia coli, and PBPs 2 and 3 in Pseudomonas aeruginosa, which are considered major lethal targets. Morphologically, tomopenem induced spherical forms in E. coli and short filamentation with bulges in P. aeruginosa, which correlated ...

Inhibitory effects of ozonated grape seed oil on Staphylococcus aureus and Pseudomonas aeruginosa

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Few long-term multicenter investigations have evaluated the relationships between aggregate antimicrobial drug use in hospitals and bacterial resistance. We measured fluoroquinolone use from 1999 through 2003 in a network of US hospitals. The percentages of fluoroquinolone-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) were obtained from yearly antibiogr...